ImageneBio, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving ImageneBio, Inc. now
Current reporting with the operating signal separated from the noise.
ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
The story matters when it changes ImageneBio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest IMA filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
10-QQuarterly financial reportFiled 2026-05-07 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-03-10 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-07-23 · Period 2026-07-20SEC ↗8-KMaterial company eventFiled 2026-06-26 · Period 2026-06-22SEC ↗8-KMaterial company eventFiled 2026-06-17 · Period 2026-06-16SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-30 · Period 2026-06-16SEC ↗3Official SEC filingFiled 2026-07-28 · Period 2026-07-20SEC ↗
ImageneBio, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →